CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Tranexamic acid +1 moredrug
Likely dose
Tranexamic acid 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00740116
NCT00740116Phase 4Completed
CompareCT.gov

Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study

Preben Kjolhede, MD, professor·interventional·Posted Aug 22, 2008·Updated Mar 15, 2022

In Brief

A Phase 4 clinical trial evaluating Tranexamic acid and 0.9% NaCl solution for Ovarian Cancer. Completed, enrolled 100 participants across 3 sites.

Detailed Summary

The purpose of the study is to determine if a standardized single dose tranexamic acid given intravenously immediately preoperatively reduces the perioperative bleeding volume and reduces the need of blood transfusion in women undergoing surgery for advanced ovarian cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesSweden
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 22, 2008
Enrollment StartMar 1, 2008
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 17.9 years ago

Interventions

Tranexamic aciddrug

Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery

0.9% NaCl solutiondrug

0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.